{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:08:12Z","timestamp":1791299292199,"version":"4.1.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T00:00:00Z","timestamp":1522108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Horizon 2020 research and innnovation program","award":["666092"],"award-info":[{"award-number":["666092"]}]},{"name":"Horizon 2020 research and innovation program","award":["653316"],"award-info":[{"award-number":["653316"]}]},{"name":"Horizon 2020 research and innovation program","award":["115843"],"award-info":[{"award-number":["115843"]}]},{"name":"St. Luke\u2019s International University (Tokyo, Japan)","award":["Research Program on Emerging and Re-emerging Infectious Diseases of the Japan Agency for Medical Research and Development (AMED)"],"award-info":[{"award-number":["Research Program on Emerging and Re-emerging Infectious Diseases of the Japan Agency for Medical Research and Development (AMED)"]}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1002535","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T13:27:27Z","timestamp":1522157247000},"page":"e1002535","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":131,"title":["Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-5482","authenticated-orcid":true,"given":"J\u00e9r\u00e9mie","family":"Guedj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Piorkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Jacquot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Madelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Huyen Tram","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Rodallec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6562-0230","authenticated-orcid":true,"given":"Stephan","family":"Gunther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Carbonnelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7045-1275","authenticated-orcid":true,"given":"France","family":"Mentr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Raoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"de Lamballerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,3,27]]},"reference":[{"key":"ref1","article-title":"Situation report: Ebola virus disease","year":"2016"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e1001967","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"D Sissoko","year":"2016","journal-title":"PLoS Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e0162199","DOI":"10.1371\/journal.pone.0162199","article-title":"Experimental treatment of Ebola virus disease with brincidofovir","volume":"11","author":"J Dunning","year":"2016","journal-title":"PLoS ONE"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A Randomized, controlled trial of ZMapp for Ebola virus infection","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e1001997","DOI":"10.1371\/journal.pmed.1001997","article-title":"Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial","volume":"13","author":"J Dunning","year":"2016","journal-title":"PLoS Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for Ebola virus disease in Guinea","volume":"374","author":"J Van Griensven","year":"2016","journal-title":"N Engl J Med"},{"key":"ref7","article-title":"Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola","year":"2015"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"L Oestereich","year":"2014","journal-title":"Antiviral Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"SJ Smither","year":"2014","journal-title":"Antiviral Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40262-015-0364-1","article-title":"Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials","volume":"55","author":"V Madelain","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2017.01.017","article-title":"Implementation of a non-human primate model of Ebola disease: infection of Mauritian cynomolgus macaques and analysis of virus populations","volume":"140","author":"G Piorkowski","year":"2017","journal-title":"Antiviral Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e0005389","DOI":"10.1371\/journal.pntd.0005389","article-title":"Favipiravir pharmacokinetics in Ebola-infected patients of the JIKI trial reveals concentrations lower than targeted","volume":"11","author":"THT Nguyen","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e01305","DOI":"10.1128\/AAC.01305-16","article-title":"Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses","volume":"61","author":"V Madelain","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1473-3099(14)71047-3","article-title":"Dose regimen of favipiravir for Ebola virus disease","volume":"15","author":"F Mentr\u00e9","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"X Qiu","year":"2014","journal-title":"Nature"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1128\/JCM.39.11.4125-4130.2001","article-title":"Development and evaluation of a fluorogenic 5\u2032 nuclease assay to detect and differentiate between Ebola virus subtypes Zaire and Sudan","volume":"39","author":"TR Gibb","year":"2001","journal-title":"J Clin Microbiol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2015.07.003","article-title":"Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever","volume":"121","author":"BB Gowen","year":"2015","journal-title":"Antiviral Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"T Baranovich","year":"2013","journal-title":"J Virol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e0164691","DOI":"10.1371\/journal.pone.0164691","article-title":"Lethal mutagenesis of hepatitis C virus induced by favipiravir","volume":"11","author":"AI de \u00c1vila","year":"2016","journal-title":"PLoS ONE"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.virusres.2017.03.014","article-title":"Favipiravir can evoke lethal mutagenesis and extinction of foot-and-mouth disease virus","volume":"233","author":"AI de Avila","year":"2017","journal-title":"Virus Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e01400","DOI":"10.1128\/AAC.01400-17","article-title":"Extinction of West Nile virus by favipiravir through lethal mutagenesis","volume":"61","author":"E Escribano-Romero","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1128\/AAC.00649-13","article-title":"Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase","volume":"57","author":"H Sangawa","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(99)11433-8","article-title":"Influenza virus neuraminidase inhibitors","volume":"355","author":"LV Gubareva","year":"2000","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"TK Warren","year":"2016","journal-title":"Nature"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/S0002-9440(10)63591-2","article-title":"Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection","volume":"163","author":"TW Geisbert","year":"2003","journal-title":"Am J Pathol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1093\/infdis\/jiv284","article-title":"Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection","volume":"212","author":"TW Geisbert","year":"2015","journal-title":"J Infect Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Y Furuta","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/dkp274","article-title":"Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells","volume":"64","author":"DF Smee","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/cid\/ciw571","article-title":"Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705), Sierra Leone, 2014","volume":"63","author":"C-Q Bai","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e1001908","DOI":"10.1371\/journal.pmed.1001908","article-title":"Use of viremia to evaluate the baseline case fatality ratio of Ebola virus disease and inform treatment studies: a retrospective cohort study","volume":"12","author":"O Faye","year":"2015","journal-title":"PLoS Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature14442","article-title":"Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates","volume":"521","author":"EP Thi","year":"2015","journal-title":"Nature"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2214-109X(16)30243-1","article-title":"Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study","volume":"5","author":"D Sissoko","year":"2017","journal-title":"Lancet Glob Health"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1093\/cid\/cix210","article-title":"Dynamics of Ebola RNA persistence in semen: report from the Postebogui cohort in Guinea","volume":"64","author":"F Subtil","year":"2017","journal-title":"Clin Infect Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(16)30386-5","article-title":"Late Ebola virus relapse causing meningoencephalitis: a case report","volume":"388","author":"M Jacobs","year":"2016","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"AM Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in liberia","volume":"377","author":"SB Kennedy","year":"2017","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jama.2016.20644","article-title":"Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored Ebola vaccines at 1 year","volume":"317","author":"RL Winslow","year":"2017","journal-title":"JAMA"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"e2804","DOI":"10.1371\/journal.pntd.0002804","article-title":"Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever","volume":"8","author":"L Oestereich","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/infdis\/jiv522","article-title":"Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model for Lassa fever","volume":"213","author":"L Oestereich","year":"2016","journal-title":"J Infect Dis"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"8847","DOI":"10.1073\/pnas.1704011114","article-title":"Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies","volume":"114","author":"K Best","year":"2017","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1002535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T12:58:35Z","timestamp":1540213115000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1002535"}},"subtitle":[],"editor":[{"given":"Tom","family":"Boyles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,3,27]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1002535","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,27]]}}}